Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 50 50 KWIKPEN versus NOVOLIN 70 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 50 50 KWIKPEN versus NOVOLIN 70 30.
HUMALOG MIX 50/50 KWIKPEN vs NOVOLIN 70/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially in skeletal muscle and adipose tissue, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase signaling.
Novolin 70/30 is a biphasic insulin analog consisting of 70% insulin aspart protamine suspension (intermediate-acting) and 30% insulin aspart (rapid-acting). It lowers blood glucose by promoting peripheral glucose uptake, inhibiting hepatic gluconeogenesis, and suppressing lipolysis and proteolysis.
Subcutaneous injection: individualized dose based on metabolic needs, blood glucose monitoring, and prior insulin therapy. Typically administered within 15 minutes before meals or immediately after meals. Total daily dose: 0.5-1.0 units/kg/day in divided doses. For the mix 50/50, half as basal (intermediate-acting component) and half as bolus (rapid-acting component).
Subcutaneous injection, 0.5-1 unit/kg/day divided into 2-3 doses, typically before meals and at bedtime; adjust based on blood glucose monitoring.
None Documented
None Documented
0.5-1 hour (insulin lispro); terminal half-life is approximately 1 hour. Clinically, the rapid clearance allows for flexible dosing timing relative to meals.
Terminal half-life for NPH component is approximately 13 hours; regular insulin component half-life is 5-6 hours. Clinical context: Provides basal coverage for 18-24 hours.
Renal: 60-80% as metabolites; hepatic metabolism accounts for most of the remainder. Fecal excretion is minimal.
Renal: 30-80% of administered insulin is excreted via kidneys; remainder is metabolized in liver and muscle. Biliary/fecal excretion is negligible.
Category C
Category C
Insulin
Insulin